In the rapidly evolving landscape of modern biotechnology, the precision of molecular tools determines the speed of medical breakthroughs. As a Global Leading Biotinylated Peptide Synthesis specialist ...
Target is a stronger company than in 2019, with higher sales, EPS, and dividends, yet its stock is now even more undervalued versus Walmart. Q2 results show early signs of recovery, with improving ...
Blusher Me on MSN
Gen Alpha is the beauty industry’s next big target
For years, beauty brands focused on millennials, then pivoted hard toward Gen Z. Now, attention is shifting again. Gen Alpha, ...
Target continues to struggle with a broken business model, losing market share to value-focused competitors in a persistently high-price environment. TGT's Q2 earnings report showed declining net ...
Novartis is taking another shot at alpha-synuclein as a target for treating Parkinson’s disease via a $200 million upfront licensing deal with Arrowhead Pharmaceuticals. The Swiss pharma plans to use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback